Generation of two iPSC lines from ALS patients harboring C9orf72 hexanucleotide repeat expansions Authors: Dide Wu, Ana Kojic, Jay P Ross, Dong Li, Parker Walther, Neelam Goyal, Jacinda Sampson, Joseph C Wu Published: 2026 ABSTRACT AbstractThe GGGGCC hexanucleotide repeat expansion (HRE) within the C9orf72 gene constitutes the leading genetic driver of amyotrophic lateral sclerosis (ALS). This fatal neurodegenerative disorder is characterized by the systematic loss of both the upper and lower motor neurons across both the central and peripheral nervous systems. This work describes the successful reprogramming of two human induced pluripotent stem cell (iPSC) lines originating from two independent ALS patients, both of whom carry a C9orf72 HRE mutation. Validation of the two established iPSC lines confirmed the expression of pluripotency markers, normal karyotypes, and successful trilineage differentiation. Consequently, these lines provide a robust in vitro platform to model ALS and study C9orf72-mediated disease mechanisms. Resource utility The C9orf72 hexanucleotide repeat expansion (G4C2) is the most common genetic cause of amyotrophic lateral sclerosis (ALS). The iPSC lines generated from patients harboring pathogenetic expansion in C9orf72 provide an accessible and versatile platform to investigate the disease mechanisms underlying ALS. These lines can be used to model ALS and screen candidate drugs. Resource details Amyotrophic lateral sclerosis (ALS) is a severe, ultimately fatal neurodegenerative disorder characterized by degeneration of both upper motor neurons (UMN) and lower motor neurons (LMN). The predominant genetic etiology of ALS is a hexanucleotide repeat expansion (HRE) within the C9orf72 gene, accounting for 30% to 50% of familial cases and approximately 7% of sporadic instances (Masrori and Van Damme, 2020). C9orf72 is also the most frequent cause (20–25%) of familial frontotemporal dementia (FTD) and 7% of sporadic FTD cases (Marogianni et al., 2019). Symptoms can be ALS, FTD, or both ALS and FTD. At present, ALS remains an incurable condition with a distinct lack of meaningful disease-altering treatments. Induced pluripotent stem cells (iPSCs) serve as an invaluable resource for in-depth mechanistic studies and the development of precision medicine for genetically defined disorders (Liu et al., 2025). Models derived from human iPSCs can offer a crucial system for investigating the functional consequences of C9orf72 mutations and could be further utilized for drug screening platforms (Sun et al., 2024). In this study, we established two human iPSC lines (SCVIi175-A, SCVIi176-A) from peripheral blood mononuclear cells (PBMCs) of two ALS patients presenting with G4C2 HRE mutation in the C9orf72 gene (Table 1). We used a Sendai virus delivery system containing the four Yamanaka factors to reprogram PBMCs into iPSCs (Yamanaka, 2026). We observed typical pluripotent colony morphology from both iPSC lines (Fig. 1A). By utilizing reverse transcription quantitative polymerase chain reaction (RT-qPCR), we quantitatively estimated mRNA expression of NANOG and SOX2 for both novel generated lines, comparing them against well-established positive control lines and negative control iPSC-derived cardiomyocytes (iPSC-CMs) (Fig. 1B). mRNA levels of SOX2 and NANOG were comparable to those in the positive iPSC control line. Additionally, pluripotent markers, including OCT3/4, SOX2, and NANOG, were expressed on the protein level in both lines, as detected by immunostaining (Fig. 1C). Normal chromosomal integrity was confirmed for both lines through karyotype analysis using the KaryoStat Assay (Fig. 1D). Both iPSC lines were confirmed to be free of mycoplasma contamination (Fig. 1E) and demonstrated their capacity to successfully differentiate into all three embryonic germ layers (Fig. 1F). Sendai viruses were absent at passage 34 for both lines (Fig. 1G). C9orf72 repeat expansions in both lines were confirmed by repeat-primed PCR (RP-PCR; Hendricks et al., 2023), which showed the characteristic “saw-tooth” pattern (Supplementary Fig. 2). Table 1Characterization and validation.ClassificationTestResultDataMorphologyPhotographyVisual record of the line: normalFig. 1 panel APhenotypeQuantitative analysis: RT-qPCRNANOG and SOX2 are expressed in both iPSC lines and absent in differentiated CMsFig. 1 panel BQualitative analysis: Immunofluorescence (IF) stainingPositive expression of pluripotency markers in both iPSC lines: OCT3/4, NANOG, SOX2Fig. 1 panel CGenotypeWhole genome array (KaryoStat Assay) Resolution 1–2 MbNormal karyotype: 46, XX for both linesFig. 1 panel DIdentitySTR analysis16 loci tested and matched wellsubmitted in archive with journalMutation analysis (IF APPLICABLE)Repeat-primed PCR (RP-PCR) with capillary electrophoresisC9orf72 GGGGCC repeat expansion detected in both lines (characteristic saw-tooth peak pattern); absent in the healthy control line Supplementary Fig. 2 SequencingN/AN/ASouthern blot or WGSN/AN/AMicrobiology and virologyMycoplasmaMycoplasma testing by luminescence: NegativeFig. 1 panel EDifferentiation potentialDirected differentiationPositive IF staining of three germ layer markersFig. 1 panel FList of recommended germ layer markersExpression of these markers has to be demonstrated at mRNA (RT-PCR) or protein (IF) levels, at least 2 markers need to be shown per germ layerEctoderm: PAX6, OTX2Fig. 1 panel FEndoderm: SOX17, FOXA2Mesoderm: Brachyury, TBX6Donor screening (OPTIONAL)HIV 1 + 2, Hepatitis B, Hepatitis CN/AN/AGenotype additional info (OPTIONAL)Blood group genotypingN/AN/AHLA tissue typingN/AN/A Characterization and validation. Characterization of iPSC lines SCVIi175-A and SCVIi176-A derived from ALS patients harboring C9orf72 hexanucleotide repeat expansions. The iPSC passages used for panels 1A, 1C, 1D, and 1F were SCVIi175-A P34 and SCVIi176-A P34. Materials and methods Reprogramming To generate the ALS patient-specific iPSCs, we isolated mononuclear cells from ALS donor’s whole blood utilizing Percoll density gradient medium (GE Healthcare, Cat #17089109), followed by serial DPBS (Thermo Fisher Scientific, Cat #14190144) washes and maintained in StemPro-34 SFM medium (Thermo Fisher Scientific, Cat #10639011) which was supplemented with 100 ng/mL SCF (Peprotech, Cat #300-07), 20 ng/mL IL-6 (Thermo Fisher Scientific, Cat #PHC0063), 20 ng/mL IL-3 (Peprotech, Cat #200-3), 20 ng/mL EPO (Thermo Fisher Scientific, Cat #PHC9631), and 100 ng/mL FLT3L (Thermo Fisher Scientific, Cat #PHC9414). We then initiated reprogramming utilizing the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific, Cat #A16517). Transduced cells were transferred onto Matrigel-coated plates. We cultured these cells using StemPro-34 medium for 7 days. Subsequently, the medium was replaced with StemMACS iPS-Brew XF medium (Miltenyi Biotec, Cat #130-104-368). Distinct reprogrammed colonies were selected between days 10 and 15 post-transduction, allowing for the subsequent expansion and cryopreservation of the newly established ALS iPSC lines. Cell culture For routine maintenance and expansion, the iPSCs were cultured in StemMACS iPS-Brew XF medium. To mitigate cell death during single-cell dissociation, the culture medium was supplemented with 5 μM Y-27632 (Selleck Chemicals, Cat #S1049) when passage was conducted. We changed medium 24 hours post-passage, and then every 48 hours until 70–90% confluence was achieved, and cells are ready for next time of replating. During culturing, all iPSCs were stored within humidified incubators with an environment set at 37 °C along with 5% CO2 supply. Trilineage differentiation Pluripotency of the ALS-derived lines was functionally validated via directed differentiation into the ectoderm, mesoderm, and endoderm lineages. Endoderm was achieved using the STEMdiff Definitive Endoderm Differentiation Kit (STEMCELL Technologies, Cat #05110). Mesoderm and ectoderm were induced using the Human Pluripotent Stem Cell Functional Identification Kit (R&D Systems, Cat #SC027B). Immunofluorescent staining Following the aspiration of culture media and a standard DPBS wash, cellular fixation was achieved using a 15-minute incubation in 10% formalin (Sigma-Aldrich, Cat #HT501128). The fixed samples were subsequently permeabilized at room temperature for 10 minutes utilizing a 50 μg/mL digitonin solution (Sigma-Aldrich, Cat #D141). A blocking solution consisting of 1% BSA (Sigma-Aldrich, Cat #A7030) and 5% serum (Sigma-Aldrich, Cat #D9663) in DPBS was applied for 30 minutes at room temperature to reduce non-specific binding. Following the blocking step, samples were probed overnight at 4 °C with the specific primary antibodies (Table 2) prepared in the blocking buffer. Targeted proteins were subsequently detected using a 30-minute, room temperature incubation with corresponding secondary antibodies, followed by nuclear counterstaining utilizing the NucBlue Fixed Cell ReadyProbes Reagent (Thermo Fisher Scientific, Cat #R37606). Table 2Reagents details.Antibodies used for immunocytochemistry, flow-cytometry, and PCRMarkerAntibodyDilutionCompany (Cat #)RRIDPluripotency markerRabbit Anti-NANOG1:200Proteintech Cat #14295–1-APAB_1607719Pluripotency markerMouse IgG2bκ Anti-OCT-3/41:200Santa Cruz Biotechnology Cat #sc-5279AB_628051Pluripotency markerMouse IgG1κ Anti-SOX21:200Santa Cruz Biotechnology Cat #sc-365823AB_10842165Ectoderm markerGoat Anti-OTX21:200R&D Systems Cat #963273AB_2157172Ectoderm markerRabbit Anti-PAX61:100Thermo Fisher Scientific Cat #42–6600AB_2533534Endoderm markerGoat Anti-SOX171:200R&D Systems Cat #963121AB_355060Endoderm markerRabbit Anti-FOXA21:250Thermo Fisher Scientific Cat #701698AB_2576439Mesoderm markerGoat Anti-Brachyury1:200R&D Systems Cat #963427AB_2200235Mesoderm markerRabbit Anti-TBX61:200Thermo Fisher Scientific Cat #PA5–35102AB_2552412Secondary antibodyAlexa Fluor 488 Goat Anti-Mouse IgG11:1000Thermo Fisher Scientific Cat #A-21121AB_2535764Secondary antibodyAlexa Fluor 488 Donkey Anti-Goat IgG (H + L)1:1000Thermo Fisher Scientific Cat #A-11055AB_2534102Secondary antibodyAlexa Fluor 555 Goat Anti-Rabbit IgG (H + L)1:500Thermo Fisher Scientific Cat #A-21428AB_141784Secondary antibodyAlexa Fluor 647 Goat Anti-Mouse IgG2b1:250Thermo Fisher Scientific Cat #A-21242AB_2535811Primers for qPCRTargetSize of bandForward/Reverse primer (5′−3′)Sendai virus vectorsSendai virus genome181 bpMr04269880_mrHousekeeping gene GAPDH 471 bpHs02786624_g1Housekeeping gene 18S 207 bpHs03003631_g1Pluripotency marker SOX2 258 bpHs04234836_s1Pluripotency marker NANOG 327 bpHs02387400_g1Primers for RP-PCRTarget /FunctionSize of bandPrimer sequence (5′−3′)primer 1 C9orf72 flanking region; FAM-labeled locus-specific primer Variable; RP-PCR products in 6-bp incrementsFAM-TGTAAAACGACGGCCAGTCAAGGAGGGAAACAACCGCAGCCprimer 2 C9orf72 GGGGCC repeat; repeat primer with anchor tail Variable; RP-PCR products in 6-bp incrementsCAGGAAACAGCTATGACCGGGCCCGCCCCGACCACGCCCCGGCCCCGGCCCCGGprimer 3 Anchor primer N/ACAGGAAACAGCTATGACC Reagents details. Mycoplasma detection Routine surveillance for mycoplasma contamination was conducted utilizing the MycoAlert Detection Kit (Lonza, Cat #LT07–318) according to the supplier’s guidelines. Short tandem repeat (STR) analysis We isolated genomic DNA from both the generated iPSCs and the matched PBMCs. We used the DNeasy Blood & Tissue Kit (Qiagen, Cat #69504) to do the DNA extraction. Next step, we executed STR analysis using the CLA IdentiFiler Direct PCR Amplification Kit (Thermo Fisher Scientific, Cat #A44661) following the manufacturer’s protocol provided along with the kit. The amplified STR products were subsequently processed at the Stanford Protein and Nucleic Acid (PAN) Facility, where they were evaluated by capillary electrophoresis on an ABI 3130xl. Karyotyping We harvested 2 × 106 cells from each iPSC cell line at passage 34 and then used the KaryoStat Assay (Thermo Fisher Scientific) for karyotyping analysis. RNA extraction and RT-qPCR To assess the expression of pluripotency markers and verify the elimination of the Sendai virus, RNA extraction and RT-qPCR analyses were conducted. Total RNA was isolated from the generated iPSC clones, positive control iPSCs, and negative control iPSC-CMs by applying TRIzol Reagent (Thermo Fisher Scientific, Cat #15596026). Following cell harvest, RNA purification was achieved utilizing the Direct-zol RNA Microprep Kit (Zymo Research, Cat #R2062) following the provided instructions. Following extraction, RNA was then converted to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad, Cat #1708891). Quantitative PCR was subsequently conducted to assess expression levels of undifferentiated human iPSC state markers NANOG and SOX2, as well as to ensure the Sendai viral genome was no longer present, utilizing commercially available TaqMan Fast Advanced Master Mix (Applied Biosystems, Cat #4444557) with the corresponding primers as detailed in Table 2. Repeat-primed PCR (RP-PCR) To assess the C9orf72 hexanucleotide repeat expansion, genomic DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen, Cat #69504) and adjusted to 20 ng/μL. Repeat-primed PCR was performed in a 20-μL reaction containing 1 μM each of primer 1, primer 2, and primer 3, 1 × Qiagen PCR buffer (Qiagen, Cat #201203), 2.5 U Taq DNA polymerase (Qiagen, Cat #201203), 0.25 mM each of dCTP, dATP, and dTTP, 0.25 mM 7-deaza-2′-deoxy-GTP (NEB, Cat #N0445S), 5% DMSO, and 1 M betaine (Sigma-Aldrich, Cat #B0300–1VL). PCR cycling consisted of an initial denaturation at 98 °C for 10 min, followed by 10 cycles of 97 °C for 35 s, 64 °C for 2 min, and 68 °C for 8 min, and then 25 additional cycles of 97 °C for 35 s, 64 °C for 2 min, and 68 °C for 8–16 min, with the extension time increased by 20 s per cycle. PCR products were analyzed by capillary electrophoresis using an ABI 3730xl DNA Analyzer at Azenta Life Sciences. Primer sequences are listed in Table 2. Supplementary Material Resource Table:Unique stem cell lines identifier1) SCVIi175-A2) SCVIi176-AAlternative name(s) of stem cell lines1) SCVI29672) SCVI3274InstitutionStanford Cardiovascular Institute, Stanford, CA, USAContact information of distributorJoseph C. Wu, joewu@stanford.eduType of cell linesiPSCOriginHumanAdditional origin info required for human ESC or iPSCAge: 67 (SCVIi175-A), 68 (SCVIi176-A)Sex: Female (all lines)Ethnicity if known: White (all lines)Cell SourcePBMCs (all lines)ClonalityClonalMethod of reprogrammingSendai virus vectorsGenetic ModificationYesType of Genetic ModificationSpontaneous mutationEvidence of the reprogramming transgene loss (including genomic copy if applicable)RT-qPCRAssociated diseaseAmyotrophic lateral sclerosis (ALS)Gene/locusGGGGCC hexanucleotide repeat expansion (HRE) in C9orf72 (all lines)Date archived/stock dateOctober 9, 2024Cell line repository/bankhttps://hpscreg.eu/cell-line/SCVIi175-A; https://hpscreg.eu/cell-line/SCVIi176-AEthical approvalThe generation of the lines was approved by the Administrative Panel on Human Subjects Research (IRB) under IRB #29904 “Derivation of Human Induced Pluripotent Stem Cells (Biorepository)”. Resource Table: Acknowledgments This work was supported by the National Institutes of Health (NIH) R01 HL171102, UG3 TR005845, UG3 AG097135, and UM1 TR006031 (JCW) and the American Heart Association (AHA) 26CDA1615217 (AK). Supplementary data Supplementary data to this article can be found online at https://doi.org/10.1016/j.scr.2026.104085. Footnotes CRediT authorship contribution statement Dide Wu: Writing – original draft, Formal analysis, Data curation. Ana Kojic: Writing – review & editing, Methodology. Jay P. Ross: Methodology, Writing – review & editing. Dong Li: Resources, Methodology. Parker Walther: Resources. Neelam Goyal: Writing – review & editing, Resources. Jacinda Sampson: Writing – review & editing, Resources. Joseph C. Wu: Writing – review & editing, Supervision, Project administration, Funding acquisition, Conceptualization. Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Joseph C. Wu is a co-founder and scientific advisory board member of Greenstone Biosciences. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Declaration of cell line availability All lines generated in this study are available to qualified researchers for scientific purposes under an appropriate material transfer agreement (MTA). Data availability Data will be made available on request. References Associated Data Supplementary Materials Data Availability Statement Data will be made available on request.